Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for InMed Pharmaceuticals Inc. (NASDAQ: INM), a British Columbia–incorporated pharmaceutical drug development company. These documents provide detailed information on InMed’s proprietary small molecule drug candidates targeting CB1/CB2 receptors, its Alzheimer’s, ocular and dermatological programs, and the commercial activities of its rare cannabinoid subsidiary BayMedica.
Through periodic and current reports, investors can review InMed’s audited and unaudited consolidated financial statements, management’s discussion and analysis, and segment information covering both pharmaceutical development and BayMedica’s commercial operations. Filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q describe sales from BayMedica, research and development spending on programs like INM-901 and INM-089, general and administrative expenses and cash resources.
Current reports on Form 8-K document material events, including financial result announcements, progress updates on INM-901 pharmacokinetic and preclinical studies, legislative developments affecting BayMedica’s rare cannabinoid business, board appointments, and details of private placements and equity purchase agreements. Proxy materials such as the definitive proxy statement on Schedule 14A outline the agenda for the annual general and special meeting of shareholders, including director elections, auditor appointments and share issuance proposals under a Standby Equity Purchase Agreement.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points, helping readers quickly understand complex disclosures such as multi-segment financials, capital structure changes and regulatory risk discussions. Users can monitor real-time updates from EDGAR, review historical filings across multiple years and examine items related to governance, such as board composition and auditor approvals, all in one organized view for INM.
InMed Pharmaceuticals appointed John Bathery to its Board, effective October 14, 2025, and increased the Board size to six members. His term runs until immediately before the company’s 2025 Annual General Meeting. Compensation follows the standard non-employee director program, including an annual retainer of US50,000; he also signed the company’s standard indemnification agreement.
Bryan Baldasare notified the company on October 15, 2025 that he will not stand for re-election at the 2025 Annual General Meeting, citing increasing professional obligations. The company stated there is no disagreement with Mr. Baldasare on matters of operations, policies, or practices.
InMed Pharmaceuticals (INM) reported an administrative update. On October 10, 2025, the company announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, as reflected in a revised submission to Canada’s SEDAR system. The notice was furnished via an 8-K under Item 8.01, with the SEDAR filing listed as Exhibit 99.1.
InMed Pharmaceuticals (INM) appointed Neil Klompas to its board of directors, effective October 9, 2025, and increased the board size to five members. His term runs until immediately before the 2025 Annual General Meeting. The company noted there are no related party transactions or family relationships tied to his appointment.
Klompas will receive non-employee director compensation consistent with company policy, including an annual retainer of US$50,000, with potential additional amounts for committee service. InMed furnished a press release as Exhibit 99.1.
InMed Pharmaceuticals Inc. filed a current report to note that on September 23, 2025 it announced financial results for its fiscal year ending June 30, 2025 and gave a business update. The update covered its pharmaceutical drug development programs and the commercial segment of its wholly owned subsidiary, BayMedica, LLC. The related news release is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed or incorporated by reference unless specifically stated in another filing.
InMed Pharmaceuticals Inc. reported that on September 23, 2025 it announced the meeting date, record date and related details for its 2025 annual meeting of shareholders through a filing on Canada’s SEDAR system. The company is making that SEDAR disclosure available to U.S. investors as Exhibit 99.1 to this report.
The company states that the information in this report, including Exhibits 99.1 and 99.2, is being furnished rather than filed under the U.S. securities laws, which limits how it is treated for liability purposes and incorporation by reference into other securities filings.
InMed Pharmaceuticals Inc. (INM) 10-K highlights key operational progress, financing and risks. The company reported continued operating losses with a net loss widening to $8.69 million for the latest year and an accumulated deficit of about $117.2 million. Management states cash resources are sufficient into the fourth quarter of calendar 2026, but concluded there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Commercial operations at BayMedica are producing some revenues tied to bulk rare cannabinoids, and the company received gross proceeds of approximately $5.0 million from a private placement and $6.2 million from share issuances under a SEPA during the year.
On the R&D side, INM-901 (Alzheimer’s candidate) showed preclinical anti-inflammatory and behavioral benefits across multiple preclinical studies and was presented at AAIC 2025. INM-755 advanced through Phase 1 and a Phase 2 EB study (19 of 20 enrolled) with reported safety and some efficacy signals. The company holds multiple patent families across product and manufacturing processes and continues CMC, GLP and scale-up activities. Major risks disclosed include clinical, regulatory, intellectual property, manufacturing, controlled-substance regulation, Nasdaq listing compliance and cybersecurity.
Form 8-K (Item 7.01 – Regulation FD): InMed Pharmaceuticals (Nasdaq: INM) announced it will present new pre-clinical data from its cannabinoid-based INM-901 program for Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2025. The disclosure, dated 28 Jul 2025, is being furnished—not filed—so it carries no liability under Exchange Act §18 and will not be automatically incorporated into other SEC filings.
No financial results, guidance, or transactional details accompany the notice; the company simply alerts investors to an upcoming scientific presentation. Exhibit 99.1 (news release) and Exhibit 104 (XBRL cover data) are provided as furnished exhibits.
Because the information is limited to a pipeline update and occurs at the pre-clinical stage, any commercial or financial impact remains undetermined within the filing.
InMed Pharmaceuticals has announced promising new preclinical data for their drug candidate INM-901 on June 24, 2025. The research demonstrates significant reduction in inflammation in ex vivo models of neuroinflammation, strengthening the compound's potential as a therapeutic treatment for Alzheimer's disease.
Key points from the 8-K filing:
- The announcement falls under Regulation FD Disclosure (Item 7.01)
- The company is classified as an emerging growth company
- Common shares trade on Nasdaq under symbol INM
- The disclosure is being furnished rather than "filed" under SEC regulations
This development represents a significant milestone in InMed's neurodegenerative disease pipeline, though specific efficacy data and trial details were not disclosed in the filing. The news was signed off by President & CEO Eric A Adams.